Six-transmembrane epithelial antigen of the postate (STREAP): a potential target of immunotherapy of prostate cancer. by Generoso, Luca
0 
 
Università degli Studi dell’Insubria 
 
Facoltà di Scienze MM.FF.NN. 
 
Dottorato di Ricerca XXIV ciclo in 
Biologia Cellulare e Molecolare 
 







Six-Transmembrane Epithelial Antigen of 
the Prostate (STEAP): 
a potential target of immunotherapy in 
prostate cancer 
 
December 15th, 2011 
 
 
  Director of Study                                           External Supervisor 






1. Introduction 5 
1.1 The Immune System: Innate and Adaptive Immunity 5 
1.2  T Lymphocytes 6 
1.3 Tumor Immunity: tumor recognition by the cells of the immune system 9 
1.4 Immunosurveillance vs Tolerance 12 
1.5 Cancer Immunotherapy strategies 16 
1.6 Prostate Cancer Immunology and Immunotherapy 22 
1.7 Pre-clinical studies in murine model 30 
1.8 Aim of the thesis 33 
2. Materials and Methods 34 
2.1 Mice, cell lines and reagents 34 
2.2 Dendritic Cells (DC) preparation and immunization strategy 35 
2.3 Intracellular cytokine production (ICP) assay 35 
2.4 Pentamer and Tetramer Staining 36 
2.5 In vitro cytotoxicity assay 36 
2.6 In vivo tumor growth 36 
2.7 Haematopoietic Cell Transplantation and Donor Lymphocyte Infusion 37 
2.8 Histology and Immunohistochemistry 37 
2.9 Disease Score 38 
2.10 RNA extraction and Real-Time PCR 38 
2.11 Statistical Analysis 39 
3. Results 40 
3.1 DC-based vaccination with TAA and induction of an antigen-specific 
immune response in C57BL/6 mice 40 
3.2 Preventive vaccination and delay of prostate cancer growth in a 
transplantable model 43 
3.3 Persistence of functional STEAP-specific CTL in aged TRAMP mice 45 
2 
 
3.4 Immune response to the different TAA in aged TRAMP mice correlates 
with antigen expression in the prostate 50 
3.5 The vaccination against STEAP does not prevent development of the 
autochthonous tumor in TRAMP mice 51 
3.6 Allotransplantation and DC-STEAP vaccination co-operate for tumor 
remission in TRAMP mice 52 
4. Discussion 59 































Immunotherapy has been proposed as a complementary or alternative 
therapy for the treatment of advanced prostate cancer (PC), one of the 
leading causes of tumor-related mortality in men. From different approaches 
that have been tested in recent years, it is now becoming more evident that 
the choice of the appropriate antigen to target is crucial for the best outcome. 
Generally tumor-associated antigens (TAAs) undergo peripheral tolerance 
during tumor progression, which dampens the efficacy of vaccination 
protocols. It can be hypothesized that the kinetic and depth of immune 
tolerance varies depending on the timing and relative expression of the TAA. 
These differences may represent a key for successful immunotherapy 
approaches even in patients with advanced disease.  
Aim of my thesis was to investigate the dynamics of CD8+ T cells specific for 
normal tissue antigens over-expressed during the spontaneous tumor 
development and progression in the transgenic adenocarcinoma of the 
mouse prostate (TRAMP) mice, a primary model of human PC.  
We have found that Prostate Stem Cell Antigen (PSCA) and Six-
Transmembrane Epithelial Antigen of the Prostate (STEAP), two well known 
PC-associated antigens, behave differently in term of immunological 
response when compared with the transgenic Tag IV antigen, which drives 
oncogenesis in TRAMP mice. While a dendritic cells (DC)-based 
immunization was able to elicit measurable immune responses for all three 
antigens in young males affected by mouse prostate intraepithelial neoplasia 
(mPIN), aged mice affected by PC progressively lost immunity against Tag IV 
and in part for PSCA, but not against STEAP. The findings correlated with 
the amount of antigens expressed in the prostate, therefore suggesting that 
tolerance against this type of TAA follows the same rule of that induced for 
tissue-associated antigens in peripheral tissues: the more the antigen is 
expressed the more tolerance is profound.  
Finally, a combined therapy of allotransplantation and DC-STEAP 
vaccination effectively reduced tumor burden in TRAMP mice, underlying 
4 
 
how this therapeutic strategy when targeted to a reliable antigen is able to 





























1.1 The Immune System: Innate and Adaptive Immunity 
 
Host defense against microbial infection is mediated by a variety of 
mechanisms that fall into two categories: innate and adaptive (or acquired). 
While innate immunity is an evolutionarily ancient and universal form of host 
defense found in all multicellular organisms, the adaptive immune system 
exists only in the context of vertebrate physiology. 
The epithelium provides both a physical barrier to the entry of microbes and 
produces a variety of antimicrobial factors. Agents that penetrate the 
epithelium are recognized by macrophages and related cells possessing 
“pattern recognition receptors” that recognize key molecules characteristic of 
many microbial agents. These include several families of molecules, of which 
the most intensively studied are the Toll-like receptors (TLRs). Each TLR 
recognizes a distinct substance (or set of substances) associated with 
microbial agents: TLR4 recognizes lipopolysaccharides; TLR3, double-
stranded RNA; and TLR9, unmethylated CpG-containing DNA. Microbial 
sensors provide a highly efficient means to recognize potential pathogens 
and in association with the phagocytic activity of macrophages induce 
antimicrobial systems that aid in the destruction of the pathogen.  
The innate immune system also acts to recruit antigen-specific immune 
responses, not only by attracting cells of the immune system to the site of the 
infection, but also through the uptake of antigen by dendritic cells (DC) and 
its transport by these cells to lymphoid tissues where primary immune 
responses are initiated.  
Primary immune responses, or adaptive, start when a foreign antigenic 
substance interacts with antigen-specific lymphocytes under appropriate 
circumstances. The response generally consists of the production of antibody 
molecules specific for the antigenic determinants of the immunogen and of 
the expansion and differentiation of antigen-specific helper and effector T 
lymphocytes. The latter include cytokine-producing cells and killer T cells, 
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capable of lysing infected cells. Generally, the combination of the 
innate immune response and the primary adaptive response are sufficient to 
eradicate or to control the infection. 
 
1.2  T Lymphocytes 
 
 
There are two broad classes of lymphocytes: the B lymphocytes, which are 
precursors of antibody-secreting cells, and the T (thymus-derived) 
lymphocytes. T lymphocytes derive from stem cell precursors in 
hematopoietic tissue, undergo differentiation in the thymus and are then 
seeded to the peripheral lymphoid tissue and to the recirculating pool of 
lymphocytes. T cells are subdivided into two distinct classes based on the 
cell surface receptors they express. The majority of T cells express antigen-
binding receptors (TCRs) consisting of α and β chains. A second group of T 
cells express receptors made up of γ and δ chains. The αβ T cells are 
subdivided into two important sublineages: those that express the coreceptor 
molecule CD4 (CD4 T cells) and those that express CD8 (CD8 T cells). 
These cells recognize the antigen in different manners and mediate different 
types of regulatory and effector functions. CD4 T cells are the major helper 
cells of the immune system. Their helper function depends both on cell 
surface molecules such as CD154, induced upon these cells when they are 
activated, and on the wide array of cytokines they secrete when activated. 
CD4 T cells tend to differentiate, as a consequence of priming, into cells that 
principally secrete the cytokines IL-4, IL-13, IL-5, IL-6, and IL-10 (TH2 cells), 
into cells that mainly produce IFN-γ and lymphotoxin (TH1 cells) or into cells 
that produce IL-17 and related cytokines (TH17 cells). TH2 cells help B cells 
to develop into antibody-producing cells, while TH1 cells are effective 
inducers of cellular immune responses, involving the enhancement of the 
microbicidal activity of macrophages and the lysis of microorganisms in 
intracellular vesicular compartments. TH17 cells are efficient recruiters of 
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granulocytes and other cells of the inflammatory system and play a major 
role in responses to extracellular bacterial pathogens.  
T cells mediate important effector functions. Some of these are determined 
by the patterns of cytokines they secrete. These powerful molecules can be 
directly toxic to target cells and can mobilize potent inflammatory 
mechanisms. In addition, T cells, particularly CD8 T cells, can develop into 
cytotoxic T lymphocytes (CTLs) capable of efficiently lysing target cells that 
express antigens recognized by the CTLs.  
T cells are able to recognize cell-associated molecules and mediate their 
functions by interacting with antigen-presenting cells (APCs), giving rise to 
the immunological synapse. The TCR does not recognize antigenic 
determinants on intact molecule, but it recognizes a complex consisting of a 
peptide, derived by proteolysis of the antigen, bound into a specialized 
groove of a class II or class I MHC protein. Indeed, CD4 T cells recognize 
peptide–class II complexes, whereas the CD8 T cells recognize peptide–
class I complexes. The TCR's ligand (i.e., the peptide–MHC protein complex) 
is created within the APC. In general, class II MHC molecules bind peptides 
derived from proteins that have been taken up by the APC through an 
endocytic process. These endocytosed proteins are fragmented by 
proteolytic enzymes within the endosomal/lysosomal compartment, and the 
resulting peptides are loaded into class II MHC that traffic through this 
compartment. Peptide-loaded class II molecules are then expressed on the 
surface of the APC where they are available to be bound by CD4 T cells that 
have TCRs capable of recognizing the expressed cell surface peptide–MHC 
protein complex. Thus, CD4 T cells are specialized to largely react with 
antigens derived from extracellular sources. 
In contrast, class I MHC molecules are mainly loaded with peptides derived 
from internally synthesized proteins, such as viral gene products. These 
peptides are produced from cytosolic proteins by proteolysis within the 
proteasome and are translocated into the rough endoplasmic reticulum. Such 
peptides, generally nine amino acids in length, are bound by class I MHC 
molecules. The complex is brought to the cell surface, where it can be 
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recognized by CD8 T cells expressing appropriate receptors. This property 
gives the T cell system, particularly CD8 T cells, the ability to detect cells 
expressing proteins that are different from, or produced in much larger 
amounts than, those of cells of host (e.g., viral antigens [whether internal, 
envelope, or cell surface] or mutant antigens [e.g., active oncogene 
products]). 
This division of class I–binding peptides being derived from internally 
synthesized proteins and class II–binding peptides from imported proteins is 
generally correct, but there are important exceptions to this rule that are 
central for the function of the immune system. The most effective priming of 
naïve CD8 T cells occurs in response to peptide–MHC-I complexes 
expressed by DCs, and yet many viruses do not infect these cells but rather 
target other cell types. It is now recognized that viral antigens produced by 
infected cells can be taken up by DCs and loaded into class I molecules in a 
process referred to as cross-presentation. 
Once activated, CD8 T cells can exert their cytotoxicity activity. There are two 
major mechanisms of cytotoxicity. One involves the production by the CTL of 
perforin, a molecule that can insert into the membrane of target cells and 
promote the lysis of that cell. Perforin-mediated lysis is enhanced by a series 
of enzymes produced by activated CTLs, referred to as granzymes. The 
other mechanism involves the Fas ligand expresses by CTL. The interaction 
of fas ligand on the surface of the CTL with fas on the surface of the target 





1.3 Tumor Immunity: tumor recognition by the cells of the immune 
system 
 
Tumor development is associated with the acquisition of gene mutations and 
expression of neoantigens or overexpression of cellular self proteins, which 
could be target for recognition by the immune system (1). CD8+ T cells can 
recognize different non-mutated or mutated antigens. 
 
Non-mutated self antigens 
 
Cancer/testis antigens 
The first antigen shown to be recognized by human tumor reactive T cells is 
MAGE-1. It was isolated by screening a melanoma genomic DNA library 
derived from the MZ2-MEL cell line with a CTL clone that recognized MZ2-
MEL cells (2). MAGE-1 was found to be a nonmutated gene and a member 
of a large, previously unidentified gene family. The T cell epitope identified 
using the MAGE-1 reactive CTL clone was recognized in the context of the 
HLA-A1 restriction element. Several additional members of the MAGE gene 
family have now been shown to encode T cell epitopes recognized by tumor 
reactive T cells (3,4). These genes are expressed exclusively in the testes, 
but not in other normal tissues, and have been termed cancer/testis antigens. 
Testes fail to express HLA molecules and thus are not recognized by T cells 
reactive with members of this gene family. Members of the MAGE gene 
family are expressed in a variety of tumor types, including melanoma, breast, 
prostate and esophageal cancer. 
Another antigen of this family is NY-ESO-1, which was initially identified 
using the antibodies screening technique (5). It represents a cancer/testis 
antigen that is unrelated to the MAGE family of genes. The NY-ESO-1 
molecule is expressed in approximately 30% of breast, prostate, as well as 
melanoma tumors. In contrast to other antigens such as tyrosinase and 
MAGE-1, for which infrequent antibody responses have been observed, 10 
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out of 12 patients with NY-ESO-1–positive tumors possessed serum 
antibodies directed against this antigen (6). 
 
Melanocyte Differentiation Antigens 
Among these antigens there are MART-1 and Melan-A. The genes encoding 
the melanoma antigen MART-1 (7) and Melan-A (8) were isolated following 
the screening of melanoma cDNA libraries with an HLA-A2–restricted tumor 
reactive TIL and a CTL clone derived by in vitro sensitization, respectively. 
The MART-1 gene encoded a 118 amino acid protein that is expressed in 
between 80% and 90% of fresh melanomas and cultured melanoma cell lines 
(9). The majority of melanoma-reactive, HLA-A2–restricted TIL were shown 
to recognize MART-1, indicating that this is a highly immunodominant antigen 
(10,11). The MART-1 antigen is representative of a set of gene products, 
termed melanocyte differentiation antigens (MDAs) that are expressed in 
melanoma as well as in normal melanocytes present in the skin as well as in 
the retina. 
Other proteins involved in the synthesis of melanin were subsequently found 
to represent MDAs, including the gp100, tyrosinase, tyrosine-related protein 
(TRP-1), and TRP-2 gene products. 
Epitopes from many of the MDAs have been found to be recognized in the 
context of restriction elements other than HLA-A2, and in addition, epitopes 
on these molecules recognized by murine tumor reactive T cells have been 
identified. Tyrosinase (12,13), TRP-1- and TRP-2-reactive T cells (14-16) 
have been shown to these gene products in the context of a variety of HLA 
class I alleles. A peptide epitope recognized by HLA-A2–restricted, TRP-2–
reactive T cells, SVYDFFVWL (TRP-2:180-188), also represented a 
dominant epitope recognized by H-2Kb restricted T cells (17). Adoptive 
immunotherapy studies carried out using the B16 murine melanoma also 







T cells have been found to recognize also gene products that are expressed 
at low levels in normal tissues but that are overexpressed in a variety of 
tumor types. As an example, screening of an autologous renal carcinoma 
cDNA library with a tumor reactive, HLA-A3–restricted T cell clone resulted in 
the isolation of fibroblast growth factor-5 (FGF5) (19), a protein that is 
expressed only at low levels in normal tissues but up-regulated in multiple 




A variety of mutated antigens have also been identified as targets of tumor 
reactive T cells. Mutated gene products that play a role in promoting 
tumorigenesis may frequently serve as the targets of tumor reactive T cells, 
as there may have been selective pressure to maintain expression of these 
products (20-22). 
The observations made in murine studies indicating that immunization 
against an individual tumor does not generally result in cross-protection 
against multiple tumors has lead to the suggestion that mutant T cell epitopes 
represent the dominant antigens responsible for tumor rejection (23). The 
identification of mutated antigens is also difficult due to the problems with 
identifying the appropriate class I or class II restriction element and may have 
lead to their being underrepresented in studies attempting to identify human 
cancer antigens. In addition, the nature of mutated antigens may make them 
more potent targets, as T cells reactive with these epitopes may not have 
undergone the same degree of negative selection as those that are reactive 







1.4 Immunosurveillance vs Tolerance 
 
 
Although appropriate T cell activation can lead in some cases to tumor 
regression, the normal role of the immune system in controlling tumor 
development is unclear. Burnet and Thomas theorized in the 1950s that the 
immune system plays an important role in preventing the outgrowth of 
tumors, a concept that was termed Immunosurveillance (24). More recent 
studies in mice have provided some evidence that the immune system may 
prevent the outgrowth of tumors bearing highly immunogenic antigens, while 
tumors that possess mechanisms that prevent the immune system from 
responding appropriately can grow progressively, a mechanism that has 
been termed Immunoediting (25). Factors that influence tumor cell growth 
include the immunogenicity of antigens expressed by those cells as well as 
the sensitivity to host factors that regulate immune responses. Tumors 
isolated from immunodeficient mice in many cases are rejected following 
injection into normal mice (26), and enhanced rates of tumor development in 
response to carcinogen treatment have been observed in mice that lack 
responsiveness to IFN-γ (27). Expression of pro-inflammatory cytokines such 
as IFN-γ may be necessary to overcome the effects of soluble inhibitory 
factors such as TGF-β and IL-10, as well as products expressed in T cells 
such as CTLA-4 and PD-1 that act to limit normal anti-tumor responses 
(28,29). Examination of the association between lymphocyte infiltration of 
tumor sites and patient survival has provided some support for the role of 
immunosurveillance in controlling tumor growth. The presence of tumor 
infiltrating lymphocytes (TIL) in a variety of tumor types has been associated 
with improved survival (30-32). As the presence of a higher ratio of T 
regulatory cells (Treg) to CD8+ T cells within tumors has been associated 
with poor prognosis (33-35), further analysis of tumor as well as other sites 
may be needed to evaluate this issue. 
Selective pressure exerted by the immune system can then lead to the 
outgrowth of tumor variants containing mutations that lead to the loss of 
recognition by cells of the immune system (immune escape, Fig.1). Relatively 
 
small groups of malignant or premalignant cells that avoid detection by the 
immune system initially develop random mutations, and pressure exerted by 
immune cells can then lead to the selective outgrowth
lost expression of gene products such as HLA class I mole
 
Fig.1. The Three Es of cancer immunoediting (from Gavin P Dunn, Nature Immunology 
2001). 
 
Several mechanisms have been shown to result in the loss or down
regulation of HLA class I expression. 
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 tumors have been described (36). Selective loss of an 
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 could theoretically lead to immune escape, those 
-induced ligands (MICA and MICB) that can 












escape strategy, even if there is no experimental evidence for this, and 
actively proliferating tumor cells have been found to express MICA/B 
independently of cellular stress (39). An alternative explanation for why tumor 
cells that have lost HLA class I are not destroyed by NK cells may be derived 
from the activation-inhibition model. NK cells are rapidly activated in the 
presence of stimulatory factors such as IL-12, IL-2, or type 1 IFNs that are 
released in response to inflammatory conditions associated with microbial 
infections. In the tumor microenvironment such stimulatory factors may not 
be readily available and the cross-talk between DCs and resting NK cells that 
normally leads to NK cell activation may not occur. In addition, the production 
of immunomodulatory cytokines such as TGF-β or macrophage migration 
inhibitory factor (MIF) by tumor cells may directly inhibit NK cell activation 
and function. Loss of expression of surface antigens can occur independently 
of the dysregulation of HLA class I expression. 
Defective death receptor signaling is another mechanism that may contribute 
to the survival and proliferation of tumor cells. Recent studies have shown 
the expression of the caspase-8 inhibitor cFLIP (cellular FLICE inhibitory 
protein) in various tumors. In these cases, cFLIP may render tumor cells 
resistant to death receptor–mediated apoptosis and may contribute to 
immunoresistance to T cells in vivo (40,41). Down-regulation or loss of Fas 
expression in tumors may also contribute to their resistance to apoptosis. 
Missense mutations and loss of the Fas gene have been identified in 
hematological cancers such as multiple myeloma (42) as well as in 
melanomas (43). 
Besides, like most normal tissues, tumor cells usually do not express 
costimulatory molecules such as B7-1 (CD80), B7-2 (CD86), and CD40. 
Recognition of tumor antigens by CD4+ and CD8+ T lymphocytes without 
adequate costimulation will lead to T cell anergy. 
Also some cytokines can negatively affect maturation and function of immune 
cells. Vascular endothelial growth factor (VEGF), which is a cytokine that is 
produced by most tumors, has been shown in several in vitro studies to 
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inhibit DC differentiation and maturation through suppression of the 
transcription factor NF-κB in hematopoietic stem cells (HSCs) (44).  
Finally, other immunosuppressive mechanisms involve Treg. These cells are 
crucial for the maintenance of the peripheral self-tolerance and for the 
suppression of anti-tumor responses, exerted by different mechanisms, 
among which the competition for IL-2 with effectors T cells and the secretion 
of TGF-β play a crucial role (45). Recently, it has been described a new 
population of CD11b+ IL-4Ra+ cells, known as myeloid derived suppressor 
cells (MDSC), able to inhibit antigen-activated CD8+ cells, mainly by the 
production of IL-13 and IFN-γ (46). MDSC may also overexpress both 
inducible nitric oxide synthase (iNOS) and arginase 1 (Arg1), enzymes 
involved in the metabolism of arginine. Depletion of arginine from the 
microenvironment inhibits T cell activation and proliferation, and favors T cell 
apoptosis (47). Furthermore, iNOS produces nitric oxide (NO), which 
interferes with IL-2 receptor signaling, leading to cell cycle arrest. Reactive 
oxygen species (ROS) and peroxynitrites, bioproducts of arginine 
metabolism, contribute to T cell inhibition. 
All together, these phenomena lead to the loss of an effective immune 
response against tumor antigens, a phenomenon called immune tolerance. 
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1.5 Cancer Immunotherapy strategies 
 
A wide variety of immunotherapies have been evaluated in model systems 
and are now being developed for treatment of patients with cancer, which 
include those that involve direct immunization of patients with a variety of 
immunogens (active immunotherapy), the adoptive transfer of activated 
effector cells (adoptive immunotherapy) as well as the passive 




Vaccination has been carried out using peptides either in saline or in 
adjuvants such as incomplete Freund's adjuvant, DCs that have been pulsed 
with peptides, with naked DNA encoding T cell epitopes, preparations of heat 
shock proteins prepared from tumor cells, as well as whole tumor cells and 
tumor lysates that have been pulsed on APCs. In addition, recombinant 
immunogens have been incorporated into viruses such as vaccinia, bird 
poxviruses, and adenoviruses that have been used successfully to protect 




Multiple trials have been carried out by administering peptides to patients 
either in saline or oil-in-water emulsions such as Montanide. Immunization 
resulted in the expansion of T cells reactive with peptides such as the 
dominant gp100:280–288 (49) and tyrosinase:369-377 (50) peptides; 
however, the levels of T cells reactive with these epitopes was generally less 
than 0.01% of peripheral CD8+ T cells. Similar levels have been observed 
using recombinant viral vaccines directed against epitopes derived from 
carcinoembryonic antigen (51) and prostate-specific antigen (52). Prime-
boost regimens employing immunization with recombinant viral constructs 
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followed by boosting with peptide immunization is a strategy that has been 
found to result in enhanced frequencies of T cells reactive with viral epitopes. 
Multiple peptides have also been used to vaccinate patients, in attempts to 
circumvent the escape of antigen loss variants. Evidence has been 
presented indicating that it is possible to generate T cell responses directed 
against multiple melanoma antigens (53), and increased frequency of T cells 
reactive with multiple peptides used for immunization were observed in 
peripheral blood as well as in sentinel lymph nodes that drained the 
immunization site (54).  
Although the expansion of T cells directed against the immunizing peptide 
was generally observed in these trials, generally less than 5% of the treated 
patients demonstrated clinical response (55). 
 
Whole cells vaccines 
 
Clinical trials employing whole tumor cells as vaccines were used to activate 
cells reactive against multiple antigenic targets. Early model studies have 
demonstrated the ability of autologous tumor cell vaccination to protect mice 
from subsequent tumor inoculation (56,57). Treatment with a combination of 
three irradiated allogeneic melanoma cells with BCG (Canvaxin trial) resulted 
in an overall survival rate of 49%, as opposed to a rate of 37% in patients 
with melanoma who did not receive the vaccine (58). Further evaluation of 
this approach in phase III trials, however, showed no significant difference in 
survival of patients with stage III or IV melanoma receiving this treatment 
compared to controls receiving BCG alone (59). 
Also genetic modified cells have been evaluated for their effectiveness in 
cancer therapy protocols. In a murine model system, mice that were 
immunized with B16 melanoma cells transduced with genes encoding 10 
cytokines were examined for their resistance to a subsequent inoculation of 
the wild-type B16 tumor (60). The results indicated that tumors transduced 
with the GM-CSF gene provided significant protection against B16 tumor 
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challenge, and a lower level of protection was observed in mice immunized 




Other approaches have used immunization with professional APCs such as 
autologous DC. One approach has employed immunization of prostate 
cancer patients with DCs that have been transfected either with mRNA 
encoding individual tumor antigens or bulk mRNA isolated from tumor cells 
(61,62). Although expansion of tumor reactive T cells following these 
treatments has been reported, only sporadic cases of tumor regression were 
observed in these trials. In one study carried out by the Dendreon 
Corporation (Seattle, WA), an APC vaccine loaded with an antigen called 
prostatic acid phosphatase linked to GM-CSF was used to treat men with 





In some clinical trials recombinant viral constructs or naked DNA encoding 
particular tumor antigens have been used. In these trials, recombinants 
containing either full-length gene products or mini-genes containing individual 
or multiple T cell epitopes were evaluated. The dominance of viral epitopes 
led to the failure in general to detect enhanced precursor frequencies 
directed against the tumor antigens.  
In studies carried out in a mouse model system, evidence for enhanced 
immunity was obtained following immunization with a recombinant virus that 
contained the genes encoding the candidate tumor antigen CEA along with 
genes encoding LFA-3, ICAM-1, and B7-1, termed TRICOM (64). In a phase 
I clinical trial, injection of a vaccinia virus TRICOM construct directly into 
melanoma lesion resulted in one partial response and one complete 
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response out of the 12 treated patients (65). Larger randomized patient 
studies will be needed to establish the efficacy of this approach.  
All these vaccination strategies achieved the goal of increasing the 
frequencies of CD8+ T cells in the blood of patients. However, only in some 




One explanation for the poor response observed in active vaccines trials 
could be due to the pre-treatment conditioning and poorly immunogenic 
vaccine formulations (66).  
To overcome the low frequencies of antigen-specific T cells and to expand 
these cells, in some preclinical and clinical trials it has been used an 
Adoptive T cells transfer (ACT) therapy. It consists in the infusion of various 
mature T cell subsets, that can be classified as autologous or allogenic 
depending on the T cell sources, in order to eliminate tumors and eventually 
prevent their recurrence (67). Among these, ACT therapy with autologous T 
cells has been well studied for the treatment of solid tumors, (melanoma) 
(68). 
Adoptive cell transfer (ACT) therapies accomplish T cell stimulation ex vivo 
by activating and expanding autologous self-/tumor reactive T cells to large 
numbers that are then transferred back to the patient (69). In the case of 
melanoma patients, tumor reactive T cells were obtained from tumor 
infiltrating lymphocytes (TIL) and then re-infused into the patients in 
combination with IL-2 with success (70).  
From retrospective studies, it is now becoming more and more relevant the 
importance of the subset of T cells transferred to the patient. ACT therapies 
should be now performed with long-lasting T central memory (TCM) and T 
stem cell memory (TSCM) cells able of long-term immunosurveillance as well 
as tumor eradication (71).  
Another critical issue in ACT therapies include host preconditioning. In an 
animal model of melanoma, the transfer of in vitro cultured TCR transgenic 
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CD8+ cells reactive against a self/tumor antigen gp100 caused substantial 
tumor regression of s.c. B16 melanoma tumors (72), and the efficacy of this 
treatment could be improved by prior recipient lymphodepletion (73). This 
strategy is able to remove endogenous cellular elements that acts as a 
“sinks” for common gamma chain cytokines (IL-7 and IL-15), capable of 
improving the efficacy of adoptively transfer tumor-specific CD8+ T cells by 
enhancing their functional capacity. Lymphodepletion may also reduce the 
number of CD4+CD25+FoxP3+ Treg cells, reducing the immune tolerance of 
the microenvironment (74). Lymphodepletion also provides “space” allowing 
for homeostatic expansion of the infused T cells and DC activation by 
microbial translocation from gut microflora (75). 
To support large-scale trials, alternative ACT treatments have been 
developed in more recent years. For instance, TCR gene transfer has 
recently emerged as a potential alternative strategy. PBMCs are modified by 
the introduction of tumor antigen-specific receptors to improve the efficacy of 
these cells for ACT therapy (76). For the introduction into the lymphocytes of 
specific genes, retroviral and lentiviral vectors have been used with success. 
To reduce the influence of endogenous TCR chains in forming new pairing 
with the inserted chains (mispairing), murine constant region sequences or 
cystine residues that favor the pairing between inserted chains have been 
used (77).  
Recently, the generation of chimeric TCR has improved a lot this strategy. In 
this case antibodies are directly fused to intracellular T-cell signaling chains 
such as CD3. Thus, chimeric lymphocytes can avoid the limitation of MHC 
restriction and specifically recognize cell surface TAAs (77). Although this 
therapy mediated the regression in patients with metastatic melanoma (78), 




Passive immunotherapy is a strategy aimed at targeting specific tumor 
antigens or stromal molecules with neutralizing antibodies. The 
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administration of monoclonal antibodies against tumor antigens in HER2-
positive breast cancer (Trastuzumab) (79), B-cell lymphoma (Rituximab) (80), 
and head and neck, lung and colorectal cancer that expresses the epidermal 
growth factor receptor (Cetuximab) is clinically effective (81). Efforts are 
ongoing to produce monoclonal antibodies with new effectors functions 
against known antigens. Among the antibodies directed against other 
molecules than antigens there is the Bevacizumab, directed against the 
vascular endothelial growth factor (VEGF) (82), while among the cytokine 
specific therapies, there is the infusion of IL-2 for the treatment of patients 
with metastatic melanoma and renal cancer.  
Recent studies in tumor immunology have focused on the concept of immune 
checkpoints, a series of molecules that function to limit an ongoing immune 
response. Administration of a blocking antibody direct against Cytotoxic T 
Lymphocyte Antigen 4 (anti-CTLA-4) has been shown to result in enhanced 
regression in murine tumor model systems when administered in combination 
with an anti-CD25 antibody and tumor vaccination (83) or with antibodies 
directed against activating molecules such as 4-1BB (84). CTLA4 blockade 
has been evaluated in several malignancies, but the most well-developed 
data come from trials in patients with melanoma, in which the blocking agent 
is associated with an approximate 10% objective response rate but, also, a 
significant rate (25–35%) of clinically important immune-related toxicity (85-
86). The specific antibody (Ipilimumab) was recently approved by the FDA for 
the treatment of metastatic melanoma. 
Another immunological checkpoint that has been targeted recently in clinical 
trials is that mediated by the molecule known as programmed cell death 1 
(PD1). PD1 was initially identified in a library-based screen of CD8+ T cells 
undergoing apoptosis (87). Subsequent work identified the ligand for PD1 as 
B7-H1 (also known as PDL1) (88,89) and showed that the interaction 
between PD1 and B7-H1 leads to an inhibition of T cell function. In animal 
studies, PD1 blockade potentiates an antitumor immune response (90-92) 




1.6 Prostate Cancer Immunology and Immunotherapy 
 
 
In the western world, prostate cancer is the most common non-cutaneous 
cancer in men, and it ranks third overall in terms of mortality (behind lung 
cancer and colon cancer) (94).  
As is the case for most types of cancer, the precise etiology of prostate 
cancer is unknown; however, a great deal of literature supports the 
hypothesis that both genetic (95) and environmental (96) factors are 
important. Interestingly, human (97) and animal studies indicate that 
inflammation might have a role in prostate cancer development, as well as in 
the progression from organ-confined to metastatic disease (98,99). Like most 
solid tumors, prostate cancer generally progresses through a series of 
stages, known as clinical states (100). 
In developed countries, many cases of prostate cancer are initially detected 
by monitoring the levels of Prostate-Specific Antigen (PSA) in the blood. 
Increased (or changing) levels of PSA prompt a biopsy, and a diagnosis of 
prostate cancer is based on microscopic evaluation of the biopsy specimen. 
Diagnosis generally leads to an attempt at local treatment, with either surgery 
or radiotherapy. For up to 80% of surgically treated men, local treatment is 
successful in that metastatic disease does not occur within 15 years (101). 
When disease does recur, the initial manifestation is often a rising PSA level 
without radiologically detectable metastases, a clinical state known as 
biochemical progression (102,103). Men with biochemically recurrent disease 
can be treated with androgen ablation, through either surgical or chemical 
castration (104). Eventually, many men with recurring prostate cancer 
develop metastatic disease, despite androgen ablation. This disease state is 
known as metastatic, castration-resistant prostate cancer and there are few 
therapeutic agents for this state of the disease. Among these, the Docetaxel 
has been approved in Europe. This is also the state in which most 
immunotherapy approaches have been clinically evaluated. These men have 
a median survival of ~16 months (105,106).  
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The goal of most approaches of prostate cancer immunotherapy is to activate 
and/or increase the population of effector T cells, which can then traffic to 
evolving tumor and mediate the specific lysis of cancer cells. Several studies 
identified self antigens overexpressed in human prostate specimens. Among 
these, not only PSA, but also other antigens have been discovered, such as 
Prostatic Acidic Phosphatase (PAP), Prostate-Specific Membrane Antigen 
(PSMA), Prostate Stem Cell Antigen (PSCA), and Six-Transmembrane 
Epithelial Antigen of the Prostate (STEAP) (107-109). Different approaches 
of immunization based on these antigens have been used in past years. 






Poxvirus vectors were extensively used in different clinical trials of prostate 
cancer. In vivo, they infect epithelial cells that undergo cell death. Cellular 
debris, including encoded antigens, are then taken up by nearby immature 
APCs, which, when appropriately activated, can present these antigens to 
CD4+ and CD8+ T cells in a pro-inflammatory context. Direct infection of 
APCs, particularly the Langerhans cells in the skin, is another mechanism by 
which poxvirus vectors can prime an immune response. For prostate cancer, 
PSA-targeted vaccinia virus-based immunotherapy has proceeded through 
several steps, including the incorporation of PSA DNA encoding co-
stimulatory molecules (lymphocyte function-associated antigen 3 (LFA3), 
CD80 and intercellular adhesion molecule 1 (ICAM1); known as TRICOM) 
into the vaccine (110), as well as optimization of the MHC class II-binding 
properties of the vaccine antigen (111). The main disadvantage of poxvirus-
based vectors results from their propensity to induce a strong antibody 
response that makes homologous prime–boost regimens ineffective, as the 
antibody response to viral proteins dominates over the desired response to 
encoded antigen (112). To circumvent this immunological limitation, a semi-
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heterologous prime–boost strategy involving a vaccinia virus prime followed 
by an analogous fowlpox virus boost (ProstVac VF–TRICOM; Bavarian 
Nordic) was optimized (112). The clinical development of this agent has been 
recently reviewed (113), and includes several trials in which ProstVac VF 




Different clinical trials using dendritic cells have been carried out in recent 
years. DCs pulsed with Prostate Stem Cell antigen (PSCA) and PSA were 
used in a Phase I/II clinical trial. This immunization protocol was able to 
induce an immune response in hormone and chemotherapy-refractory 
patients. This response correlated with an increase in overall survival (115). 
The most advanced study regarding the use of DCs to induce an immune 
response is that referred to Sipuleucel-T (Provenge; Dendreon Inc.) This is a 
personalized product that is individually manufactured for each patient with 
prostate cancer (116). First, leukopheresis is carried out, and monocytes are 
enriched in the leukopheresis product through density–gradient 
centrifugation. These cells are then incubated with the targeted immunogen, 
a fusion protein linking granulocyte–macrophage colony-stimulating factor 
(GM-CSF) to Prostatic Acid Phosphatase (PAP), before intravenous 
administration. Once infused, these autologous monocytes are thought to 
mature into functional APCs and to activate PAP-specific CD4+ and CD8+ T 
cells in treated patients. These activated T cells are then thought to home to 
tumor lesions, mediating an antitumor response. In this approach, PAP was 
chosen as the target antigen based on preclinical studies in a rat model that 
showed that tolerance to PAP in prostate cancer was not mediated by central 
deletion of PAP-specific T cells, such that PAP-directed vaccination could 
induce marked T cell infiltration into the prostate gland (117). In terms of 
clinical development of immunotherapies for prostate cancer, this agent has 
progressed the furthest: three Phase III studies have been completed (63) 
and US Food and Drug Administration (FDA) approval was granted in April 
 
2010, making Sipuleucel
for cancer treatment. 






it straightforward to target nearly any selected antigen
disadvantage of DNA
relative to the highly immunogenic viral vectors described above. To improve 
the outcome, pro-inflammatory molecules 
type 1 tegument protein VP22 (to enhance spreading from transfected cells 
to DCs) or Toll-like receptor (TLR) agonists (to activate APCs) 
incorporated into DNA
administered with GM
CSF was used with the aim of recruiting
vaccine site (120). A recent clinical study
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— such as herpes simplex virus 
-based vaccines (119), or the vectors have been co
-CSF as a nonspecific adjuvant. In this context, GM
 APCs, particularly DCs, to the 
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of DNA-based vectors in men with prostate cancer: in a population of men 
with biochemically recurrent disease given a DNA vaccine encoding PAP, 
PAP-specific T cell responses were induced, as well as an inhibition of the 
rate of PSA level increase. 
 
Whole cells vaccines 
 
The use of whole cells vaccines for prostate cancer is known as GVAX 
(BioSante) (122). This formulation includes GM-CSF-transduced tumor cells 
used as a vaccine. Such cells are injected intradermally; the GM-CSF 
attracts APCs and T cells to the vaccine site, thereby priming an immune 
response to tumor antigens. Earlier GVAX trials attempted to engineer a 
vaccine using autologous tumor cells from individual patients (123), but it was 
later appreciated that tumor antigens can be cross-presented on patients' 
APCs (124), so further clinical development focused on allogeneic tumor cell 
lines of a particular cancer type transduced to secrete GM-CSF. This 
approach has been developed for several types of cancer, including prostate 
cancer (125). Prostate GVAX, for example, includes the androgen-sensitive 
prostate cancer cell line LNCaP, as well as the castration-resistant prostate 
cancer cell line PC3, and early phase clinical trials suggested that prostate 
GVAX could induce new antibodies specific for the cell lines injected (126). 
Similar to Sipuleucel-T, clinical development of prostate GVAX has advanced 
to the level of randomized Phase III clinical trials. However, for various 





Passive immunotherapy aim at targeting specific tumor antigens with 
neutralizing antibodies. Prostate-specific Membrane Antigen (PSMA) is 
overexpressed on tumor-associated vasculature, as well as on the cell 
surface of prostate cancer cells, making this agent potentially applicable to 
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other types of cancer (128). Early clinical trials of a humanized, PSMA-
specific antibody (J591; Cornell Weill Medical College) showed impressive 
tumor targeting, but few objective clinical responses were noted in the 
patients with advanced tumors who were included in these studies (129). 
Similar to monoclonal antibodies developed for the treatment of other types 
of cancer, the current development of J591 has progressed to a radioisotope-
labeled version, with the goal of mediating cancer cell death by localizing a 
radioactive β-ray emitter close to a patient's tumor mass (130). Several trials 
involving 177Lu-labelled J591 are currently in progress, including studies 
combining this agent with conventional cancer therapy.  
Among the Immune checkpoint blockade, Ipilimumab has been evaluated in 
several Phase I and Phase II trials in patients with prostate cancer, and 
objective clinical responses and decreases in PSA levels have been 
described (131). Based on those data, a Phase III trial comparing Ipilimumab 
with a placebo is currently underway in men with castration-resistant 
metastatic disease who have not responded to prior chemotherapy 
(clinicaltrial.gov). 
PD1 has been less well studied in prostate cancer, although it was found that 
the CD8+ T cells that infiltrate the prostate gland in men with cancer seem to 
express PD1 (132). A Phase I clinical trial of a fully human monoclonal 
antibody targeting PD1 has been completed, with interesting results (133). 
First, this agent was remarkably well tolerated, with few serious adverse 
events noted. Second, several objective clinical responses were noted in 
patients with various types of cancer. Taken together, these data reinforce 
the relative importance of immune checkpoint blockade in tumor 
immunotherapy. 
 
In recent years, it is becoming more and more relevant how cancer 
immunotherapy need to be combined with conventional therapy to achieve 
maximal patient benefit. Fortunately, many conventional treatments for 
prostate and other cancers have beneficial immunological effects, making 
combinatorial trials an attractive proposition. Even chemotherapy, which is 
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broadly viewed as immunosuppressive, might to some extent boost an 
antitumor response (134). Recently also the androgen ablation has been 
revised from a clinical point of view. The immunological effects of androgen 
ablation are surprising because they involve also the thymus, which is 
generally not thought of as an androgen-sensitive organ (135). In aged mice, 
androgen ablation seems to result in regeneration of the normally involuted 
thymus and in the output of new T cells in peripheral blood (136). Similar 
effects have been observed in humans were in some trials androgen ablation 
before prostate cancer surgery results in the infiltration of activated CD4+ T 
cells into the prostate gland (137). Also recent data showing the induction of 
new antibody specificities in treated patients support a pro-immunogenic role 
for androgen ablation (138,139). For these reasons, this therapeutic 
approach has been evaluated in several clinical trials. An early study tested 
one dose of vaccinia virus–PSA vaccine (ProstVac) in combination with 
androgen ablation, finding the combination to be well tolerate (140). In a later 
randomized study, immune responses to ProstVac were more commonly 
observed in men who received androgen ablation after active immunotherapy 
(141), as opposed to receiving androgen ablation before immunotherapy. 
Taken together, these studies support the notion that combined immune and 
hormonal therapy might be clinically interesting and worthy of further 
evaluation.        
Also radiotherapy has been revised recently in combination studies. Although 
the cytotoxic effects of radiation therapy are well-known, recent data support 
the notion that irradiation of cancer cells can prime an antitumor immune 
response (142). On a cellular basis, this process seems to involve the uptake 
of dying tumor cells by APCs (143) and the presentation of tumor antigens to 
immune cells, as well as the induction of a pro-inflammatory 
microenvironment by the radiation (144). In patients with prostate cancer, 
evidence for an immunological effect of radiotherapy is provided by data 
showing the induction of new antibody specificities following radiotherapy 
treatment (147). Although the molecular mechanisms for these 
immunological effects of radiotherapy are complex, recent work has shown 
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that high mobility group box 1 (HMGB1) released from dying tumor cells can 
function as a TLR4 agonist, activating APCs in either the tumor parenchyma 
or in the draining lymph node, and so priming an immune response (142). 
These immunostimulatory effects are not unique to radiation-induced tumor 
cell death, but can also be elicited when tumor cells are killed by certain 
chemotherapy agents. Several preclinical studies support the notion that 
combining irradiation with immunotherapy can be either additive or 
synergistic in terms of the antitumor response (145,146). This concept has 
been evaluated clinically in a small randomized trial of men undergoing 
primary radiotherapy for prostate cancer (147); 13 out of 17 patients in the 
radiotherapy and immunotherapy combination treatment group had a greater 
than threefold increase in the number of PSA-specific T cells, whereas no 
increase in the number of PSA-specific T cells was noted in the group that 
received radiotherapy alone. However, as is the case for combining 
chemotherapy with immunotherapy, the relative sequencing of agents might 
be crucial (148). 
 
1.7 Pre-clinical studies in murine model
 
Murine models represent a unique tool to study in vivo the effects of new 
vaccination protocols against prostate cancer. The vast majority of 
immunotherapeutic settings were tested in the Transgenic Adenocarcinoma 
of the Mouse Prostate (TRAMP) model. 
SV40 early genes (large T and t antigens; Tag) expressed under the control 
of probasin regulatory element (
thymus causes deletion of high avidity T cell clones, in the periphery Tag is 
selectively expressed in prostate epithelial cells under the influence of sex 
hormones. Animals remain Tag
(wk) 4-5]. In the following weeks all TRAMP mice invariably and 
progressively develop mouse prostate intr
12), adenocarcinoma (wk 12
(wk 18-30, Fig.3).  
                      Fig.3. Progression of prostate cancer in TRAMP mice.
 
TRAMP mice are transgenic for the 
149). While marginal expression of Tag in the 
-negative and healthy until the puberty [i.e. 
aepithelial neoplasia (mPIN; wk 6








TRAMP mice castrated at wk 12, almost invariably (80%) develop a hormone 
refractory PC within 10-12 wk (149). Thus, cancer development, androgen 
sensitivity, fine aspects of neo-angiogenesis and metabolic activity in TRAMP 
mice resemble human PC. In TRAMP mice, the large T encoded antigen 
(Tag) behaves as a TAA. Disease progression in these mice correlates with 
induction of tumor-specific peripheral T cells tolerance (150), which 
recapitulates the tolerance state found in patients with advanced disease. 
Thus, TRAMP mice have documented progression to invasive carcinoma of 
epithelial origin and metastasis closely resembling the human pathology. 
At 6-7 weeks of age a single vaccination with dendritic cells (DC) pulsed with 
the Tag-derived immunodominant CTL epitope Tag-IV elicits the induction of 
Tag-IV-specific CTL. However, TRAMP mice older than 10 weeks fail to 
respond to DC-mediated vaccination. This suggests that during the course of 
PC progression, mice become progressively tolerant to Tag (150).                              
In the studies conducted in TRAMP mice different immunogenic strategies 
have been used. Prostate Stem Cell Antigen (PSCA) DNA followed by an 
heterologous boost of mPSCA-VRP (virus replicating particles) is able to 
induces CD4+ and CD8+ T cells that delay prostate cancer growth in a 
transplantable model (TRAMP-C1 tumor) (151). A similar strategy of priming 
and boosting was able to delay prostate cancer growth in both young and old 
TRAMP mice, even if a castration step in old TRAMP mice was necessary to 
obtain the therapeutic effect (152). Also the vaccination with a plasmid coding 
for murine PSCA delivered i.m. was able to delay TRAMP-C1 growth in 
C57BL/6 mice. The immune response obtained in these mice was increased 
with an adoptive transfer (AT) of splenocytes of immunized WT mice (153). 
Another antigen that was used in the immunization protocols is Six-
Transmembrane Epithelial Antigen of the Prostate (STEAP).  STEAP-based 
vaccination is effective in vivo in prophylactic models. Using CD4 or CD8 
knockout mice it was evident how not only CD8 but also CD4 play a relevant 
role in the immune response against prostate cancer. Unfortunately, a 
therapeutic protocol based on this approach did not completely control tumor 
growth (154). DCs pulsed with TRAMP-C1 tumor lysates were used as 
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immunogen in a preventive setting of vaccination with a priming of 
recombinant adenoviruses coding for PSCA, STEAP and PSMA (155). These 
results demonstrated how the prophylactic protocol is the only one able to 
significantly control tumor growth. STEAP protein was scored by MHC 
peptide binding algorithms to predict potential STEAP sequences capable of 
stimulating in vitro naïve CTLs. Different sequences have been tested in vitro 
for their capacity to stimulate HLA-A2-restricted CTLs (156) or in vivo in HLA-
A*0201 transgenic HHD mice (157). Among these, different sequences were 
able to induce a STEAP-specific immune response and have been proposed 
















1.8 Aim of the thesis 
 
The aim of this thesis project was to evaluate the immune response against 
prostatic antigens such as PSCA and STEAP in C57BL/6 WT and prostate 
cancer-prone TRAMP mice, and to compare this response to that obtained 
with Tag IV immunization. Major goal was to investigate the dynamic of 
tolerance induction for this two tumor antigens over-expressed during 
spontaneous tumor development and progression in TRAMP mice. To do 
that, a dendritic cells (DC)-based vaccination strategy will be used, followed 
by a comparative gene expression analysis of different TAA, in order to 
dissect a possible molecular mechanism underlying the different immune 
response to various antigens.  
 



















2. Materials and Methods 
 
2.1 Mice, cell lines and reagents 
 
 
C57BL/6 mice (H2b) were purchased from Charles River (Calco, Italy) and 
were bred in the Institutional specific pathogen-free animal facility. 
Heterozygous TRAMP mice on a C57BL/6 background (149) were housed 
and bred in our animal facility, treated in accordance with the European 
Union guidelines, and with the approval of the Institutional Ethical Committee. 
TRAMP mice were typed for Tag expression by PCR-based screening. 
Isolation of mouse-tail genomic DNA was performed by digestion with NaOH. 
RMA is a H2b Rauscher virus-induced thymoma. TRAMP-C1 cells are a 
stable cell line derived from murine prostate cancer specimen (158). B6-k0 
cells are SV40 transformed kidney cells that express Tag IV (150). For in 
vitro studies, 3x107 spleen cells were cultured for 5 days in RPMI medium 
supplemented with 2mM L-glutamine, 100U/mL Streptomycin/Penicilin, 50µM 
β-mercaptoethanol, 10µM Hepes, 1mM sodium  pyruvate (Invitrogen Life 
Technology, Milan, Italy) and 10% heat-inactivated fetal bovine serum (FBS, 
Euroclone, Milan, Italy) at 37°C in a 5% CO2 atmosphere. For PSCA 
restimulation, spleen cells were co-culture with Kb specific PSCA83-91 peptide 
(NITCCYSDL), while for STEAP186-193 restimulation spleen cells were co-
cultured with Kb specific STEAP peptide (RSYRYKLL). RMA cells were 
maintained in RPMI medium supplemented with 2mM L-glutamine, 100U/mL 
Streptomycin/Penicilin, 50µM β-mercaptoethanol, 10µM Hepes, 1mM sodium 
pyruvate and 10% heat-inactivated fetal bovine serum at 37°C in a 5% CO2 
atmosphere. TRAMP-C1 cells were maintained in DMEM medium 
supplemented with 2mM L-glutamine, 100U/mL Streptomycin/Penicilin and 
10% FBS at 37°C in a 5% CO2 atmosphere.                                                             
All antibodies for Flow Cytometry were purchased from BD Pharmingen (San 
Diego, CA). These antibodies included fluorescein isothiocyanate (FITC)-
conjugated anti-CD44 (clone IM7), Peridinin-chlorophyll-protein complex 
(PerCP) Cy5.5-conjugated anti CD8a (Ly-2, clone 53-6.7), Allophycocyanin 
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(APC)-conjugated anti-IFN-γ (clone XMG1.2). Staining buffer solution 
consists on 1x PBS supplemented with 2% FBS and 0,2% sodium azide. 
Permeabilization buffer solution consists on Staining Buffer solution 
supplemented with 2% rat serum and 0,5% Saponin (Sigma). Fixation was 
performed with 2% Formaldehyde (Sigma). Before stainig (15 minutes at 
4°C), cells were incubated with FcR blocker (BD Pharmingen) for 10 minutes 
at room temperature. 
 
2.2 Dendritic Cells (DC) preparation and immunization strategy 
 
DC were prepared and characterized as previously described (159). Briefly, 
bone marrow cells were seeded into six-well plates at 2x106/mL in ISCOVE 
medium supplemented with 2mM L-glutamine, 100U/mL 
Streptomycin/Penicilin, 10% FBS, GM-CSF (25 ng/mL), and IL-4 (5 ng/mL; 
R&D Systems, Minneapolis, MN). Fresh medium was added on day 3 and 
day 5. On day 7 of the in vitro culture, LPS (1 mg/mL) was added to the cells 
for the last 8 hours of culture, and non-adherent and loosely adherent cells 
were collected. DC were pulsed with either PSCA (2 µg/mL) or STEAP (2 
µg/mL) during the last hour at 37°C, washed, and resuspended at 
2,5x106/mL in PBS. Mice were injected i.d. with 5x105 DC. Animals were 
usually sacrificed 7 days after the last vaccination, or different weeks after in 
the survival experiments. 
 
2.3 Intracellular cytokine production (ICP) assay 
 
Spleen cells were analyzed for PSCA or STEAP-specific IFN-γ release by 
intracellular staining in vitro. Briefly, splenocytes were cultured in vitro in 10% 
FBS RPMI medium in the presence of specific peptide. Day-5 cultures were 
ficolled and blast were stimulated for 4 hours with RMA cells, unpulsed or 
pulsed with 5 µg/mL of PSCA or STEAP peptide. Brefeldin A (5 µg/mL; 
Sigma) was added after 1 hour. Cells were then stained with anti-CD44 and 
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anti-CD8 antibodies for 15 minutes at 4°C, fixed in 2% Formaldehyde for 20 
minutes at room temperature, permeabilized with Permeabilization Buffer and 
further stained for 30 minutes at 4°C with anti-IFN-γ antibody. 100.000 events 
were collected in a BD FACS Canto (BD Bioscience). Dead cells were 
excluded electronically by physical parameters. 
 
2.4 Pentamer and Tetramer Staining 
 
For STEAP specific enumeration, splenocytes were stained with PE-labeled 
Kb/STEAP tetramers (kindly provided by NIH Tetramer Facility, Emory 
University, GA). Kb/OVA pentamers (Proimmune) were used as a negative 
control. Pentamer and tetramer staining were performed in combination with 
fluorochrome-labeled monoclonal antibodies against CD4,CD8, B220, CD11b 
and the vitality marker To-PRO3. 
 
2.5 In vitro cytotoxicity assay 
 
In vitro cytotoxicity was measured in standard 4h 51Cr-release assay (150). 
Briefly, targets cells were labeled with 51Cr for 1 hour and then seeded with 5 
days blasts for 4 hours in different effector:target ratios. 51Cr release of target 
cells was always < 25% of maximal 51Cr-release (target cells in 1% SDS). 
Lytic activity was estimated by 51Cr-release on the medium by killed targets 
cells. 
 
2.6 In vivo tumor growth 
 
Mice were challenged s.c. in the left flank with 2,5 x 106 TRAMP-C1 cells. 
Tumor size was evaluated by measuring three perpendicular diameters by a 
caliper. Animals were monitored twice a week and killed when the tumor 
reached approximately dimension of 15 mm of mean tumor diameter or when 
they became ulcerated. Splenocytes were harvested, cultured in vitro for 5 
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days with the relevant peptide and assessed for in vitro intracellular cytokine 
production (ICP). 
 
2.7 Haematopoietic Cell Transplantation and Donor Lymphocyte 
Infusion 
 
Mice received a sub lethal dose of total body irradiation (TBI; 600 Rad) and 
the day after were transplanted by an i.v. injection of 1x107 viable female 
bone marrow (BM) cells derived from C57BL/6 CD45.1/CD45.2 mice. BM cell 
suspensions from donor mice were prepared by flushing the medullary cavity 
of the humerus, tibia and femur with PBS. Nucleated viable cells were 
counted in Trypan Blue using a hemocytometer. Cells suspensions were 
adjusted to a final concentration of 5x107 cells/mL in PBS and 200µl/mouse 
were injected i.v. into the lateral tail vein. Donor Lymphocytes Infusion (DLI) 
consisted on a i.v. injection of 6x107 splenocytes derived from female 
C57BL/6 CD45.1 mice. DLI was performed two weeks after BM 
transplantation.  
 
2.8 Histology and Immunohistochemistry 
 
At the time of mice sacrifice, the urogenital organs were collected, fixed in 
4% formalin for 6 hours, then embedded and included in paraffin wax. 
Sections (5 µm thick) were cut, stained with H&E (Bio-Optica, Milan, Italy), 
and scored by a phatologist. Sections were also de-paraffinized in xylene, 
rehydrated in ethanol, immersed in 600 mL 10mM citric acid pH 6.0, heated 
in microwave, and cooled at room temperature. Endogenous peroxidase was 
quenched with 3% H2O2. Slides were incubated with 5% normal goat serum 
(Vector Labs, Burlingame, CA) and with primary mAb against CD3 (Serotec) 
1:200 overnight at cold, followed by incubation with rat anti-mouse (Vector 
Labs) diluted 1:100. Slides were then incubated with Vactastain Elite ABC 
(Vector Labs) following the recommended protocol. Peroxidase activity was 
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visualized using Nova Red chromogen (Vector Labs) and the counterstain 
was done with Mayer-Hematoxylin. After dehydratation in ethanol and xylene, 
slides were permanently mounted in Eukitt (Bio-Optica). CD3 sections were 
digitally scanned (ScanScope, Aperio) and then analyzed with the Spectrum 
Plus software (Aperio). 
 
2.9 Disease Score 
 
Macroscopic and microscopic specimens were evaluated by a pathologist 
blinded with respect to the treatment group to which the mice belonged (150). 
The score of 0 was given to prostates showing complete tumor regression 
(CR) and the score of 5 was given to invasive adenocarcinoma or 
metastases. Prostates with areas of CR scattered among acini affected by 
adenocarcinoma were defined as partial regression (PR). Mice bearing highly 
aggressive poorly differentiated neuroendocrine tumors were excluded from 
the study. 
 
2.10 RNA extraction and Real-Time PCR 
 
RNA from prostates of TRAMP mice at different ages was extracted with the 
RNeasy Mini Kit (Qiagen) and was quantified by measuring the absorbance 
at 260 nm. The purity of RNA was checked by measuring the ratio of 
absorbance at 260 and 280 nm, where a ration ranging from 1.8 to 2.0 was 
taken to be pure. First strand cDNA was generated from 0.5 µg of RNA using 
the M-MLV RT and M-MLV RT buffer (Invitrogen Life Technologies), 
according to the manufacturer’s protocol. Real-Time PCR was performed in a 
total volume of 20 µL using the SYBR Green PCR Master Mix (Applied 
Biosystems) and 3 µL of cDNA; specific primers for Tag IV (forward: 
GCTACACTGTTTGTTGCCCA,   reverse: CCCCCACATAATTCAAGCAA), 
PSCA (forward: TCATCTGTGCTGTGCATGAAT, reverse: 
GCTCACTGCAACCATGAAGA) and STEAP (forward: 
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GTCACTGATCTCCATGACTGCT, reverse:  GTGGGACTGGGAGTCCGT) 
were obtained from Primm (Milan, Italy). The Real-Time amplifications 
included 10 min at 95°C followed by 40 cycles at 95°C for 15 sec and 60°C 
for 1 min. To normalize the mRNA expression, house-keeping gene was 
amplified (L-19, forward: CTGAAGGTCAAAGGGAATGTG, reverse: 
GGACAGAGTCTTGTGATCTC). 
  
2.11 Statistical Analysis 
 
Statistical analyses were performed using the two-tailed Student’s t-test or 

























3.1 DC-based vaccination with TAA and induction of an antigen-specific 
immune response in C57BL/6 mice 
 
First of all we tested the capacity of the immunodominant cytotoxic T 
lymphocyte (CTL) peptide epitopes of PSCA (PSCA83-91, NITCCYSDL) and 
STEAP (STEAP186-193, RSYRYKLL) to induce an antigen-specific immune 
response in C57BL/6 WT mice. These epitopes have been previously 
demonstrated to bind MHC class I (Kb) molecules of C57BL/6 mice 
(151,154). To this aim, DC (0,5x106 cells) pulsed with PSCA83-91 or 
STEAP186-193 (2 µg/mL) were injected intradermally in the left flank of 6-8 
week-old mice. A cohort of mice was immunized with unpulsed DC as 
control. Seven days later, mice were analyzed for their capacity to mount a 
measurable immune response against PSCA or STEAP. Splenocytes from 
mice vaccinated with either PSCA or STEAP-pulsed DC were restimulated in 
vitro with the specific peptide. At day 5, blasts were challenged with RMA (a 
congenic lymphoma cell line) unpulsed or pulsed with the relevant peptide 
and assessed for intracellular cytokine production (ICP) by flow cytometry 
(Fig.1, A and B). 
Flow cytometry analyses showed a low but consistent number of CD8+ T 
cells producing IFN-γ upon challenge with the relevant antigen, but only in 
mice vaccinated with PSCA or STEAP-pulsed DC, excluding the possibility of 
in vitro priming. More importantly, the same blasts produced IFN-γ when 
challenged with TRAMP-C1 cells, a cell line obtained from the prostate tumor 
of a 32-week old TRAMP mouse (158), therefore demonstrating that T cells 




Fig.1. C57BL/6 mice vaccinated with either DC
immune response against the relevant epitope
vaccinated with PSCA (A) 
or 2 µg/mL STEAP peptide, and 5
ICP assay. Blasts were challenged with PSCA
PSCA/RMA-STEAP) and stained with fluorochrome
before flow cytometry analysis. Ce
representative of at least 3 independent
reported at the bottom of panels A and B. 
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3.2 Preventive vaccination and delay of prostate cancer growth in a 
transplantable model
 
To investigate whether CTL induced by PSCA or STEAP
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3.3 Persistence of functional STEAP-specific CTL in aged TRAMP mice  
 
Having found that a potential immune response against antigens naturally 
expressed in the prostate is maintained in adult WT mice, we asked if the 
same occurred in TRAMP mice that, starting from puberty, progressively 
develop spontaneous mPIN and prostate cancer (149). Because STEAP 
gave the best results in WT mice (Fig.4), we focused on this antigen. 
We have previously reported that young TRAMP mice (i.e. 6-8 weeks of age) 
affected by mPIN respond to a DC-based vaccination specific for the TAA 
Tag IV (150), therefore demonstrating that low-affinity Tag-specific T cells 
escape central tolerance (172) and reach the periphery, where they can be 
activated by the vaccine. In the following weeks, likely due to tumor-
associated Tag IV over-expression in the prostate, TRAMP mice 
progressively loose the capacity to respond to the vaccine and enter a state 
of full tolerance (150). Our hypothesis was that the immune response against 
all prostate TAA undergoes the same kinetic. Hence, we started by 
vaccinating young TRAMP mice with DC-STEAP. As shown in Fig.5A, 
splenocytes from young vaccinated TRAMP males produced IFN-γ in the 
presence of both STEAP-pulsed RMA and TRAMP-C1 cells.  
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All together, these results suggest that during the development and 
progression of a spontaneous tumor the immune response to TAA may 
behave differently, and 
TRAMP mice affected by prostate cancer.
 
3.4 Immune response to the different TAA in aged TRAMP mice 
correlates with antigen expression in the prostate
 
We asked if the different behavior of CTL specific for Tag IV, STEAP and 
PSCA in tumor-bearing TRAMP males could depend on the amount of 
antigen expressed in the tumor. We hypothesized that the more the antigen 
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STEAP, which showed to be the least expressed, was also the one that 
elicited the highest cytolytic response.  This correlation might explain why in 
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3.5 The vaccination against STEAP does not prevent development of 
the autochthonous tumor in TRAMP mice
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3.6 Allotransplantation and DC
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We have recently reported that allo
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recipients (165), and was required for therapeutic efficacy in the case of DLI 
from unsensitized donors (Hess Michelini R. et al. Manuscript in preparation). 
We asked whether DC-STEAP vaccination could substitute DC-Tag IV in this 
therapeutic setting. Hence, 16-17 week-old male TRAMP mice (CD45.2+) 
were preconditioned by non-myeloablative total body irradiation (TBI, 600 
Rad) and transplanted the following day with 1x107 BM cells from 
(B6.CD45.1+ x B6.CD45.2+) F1 female (HSCT). Two weeks later mice 
received a donor lymphocyte infusion (DLI) of 6x107 splenocytes from female 
(fDLI) CD45.1+ congenic donors that were not pre-sensitized against host 
minor H antigen. Blood samples were taken at different time points after DLI 
to follow the immune reconstitution. One day after DLI transplanted mice were 
vaccinated with DC pulsed with either STEAP or unpulsed DC (Fig.12 depicts 
a schematic representation of the transplant setting). At the time of sacrifice 
(42 days after HCT), splenocytes were harvested and assessed for in vitro 
ICP in the presence of RMA-STEAP. As reported in Fig.12, in DC-STEAP 
vaccinated mice a low, but consistent percentage of CD8+ T cells (from donor 





   
 
      
Fig.12. Allotransplantation and DC
response in TRAMP mice
preconditioned by non-myeloablative total body irradiation (TBI, 600 Rad) and transplanted the 
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Fig.13. Allotransplantation and DC
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Mice were blindly assigned a DS reflecting the area of residual 
transformation. The mean DS for TRA
TRAMP/fHCT/fDLI/DC was 3.8 ± 0.4, while that for TRAMP/fHCT/fDLI/DC
STEAP group was 2.4 ± 1.4. Among the
group there was 2 complete regression (CR), 4 partial regression (PR) and 
3 non responders (NR)
         
Fig.14. Allotransplantation followed by tumor
in TRAMP mice. The histology (A) of UGA was analyzed on paraffin
H&E. Panels show 5x magnification. Images from 1 representative 
Disease Score was individually assigned on coded samples. Each dot represents the disease 
score from an individual mouse. The mean disease score between TRAMP/DC
and TRAMP TRAMP/fHCT/fDLI/DC
P<0.05). Samples were also scored for CR, PR or NR, defined as described within the text.
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Fig.15. Allotransplantation followed by tumor
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The recent approval from FDA of the first vaccine against hormone-refractory 
prostate cancer, Sipuleucel-T, highlights how the choice of the antigen and 
the immunization strategy are crucial for the best outcome. In that case, the 
choice of the antigen to be used in clinical trials, PAP, was based on the 
ability of PAP-specific immunization to break peripheral T cell tolerance (117, 
fda.gov/downloads/biologicsbloodvaccines/.../ucm227998.pdf). However, a 
clear demonstration either in mice or humans that the therapeutic efficacy of 
sipuleucel-T correlates with a PAP-specific immune response is still lacking. 
This might account for the limited success of the trial (63), and underlines the 
need for a better understanding of the dynamics of the immune response 
against TAA in cancer patients. 
We have reported here that in the reliable TRAMP model, prostate cancer-
associated antigens may behave differently in term of immunological 
response and long-term protection against tumor progression. 
Firstly, we demonstrated that a DC-based vaccination against two well-
known self-antigens, PSCA and STEAP, over-expressed during prostate 
cancer progression (108,109), can elicit specific CTL that recognize the 
appropriate target in C57BL/6 WT mice. These preliminary experiments 
underlined how a single immunization was able to induce a specific response 
in the treated animals. Besides, PSCA and STEAP-specific CTL were also 
able to delay TRAMP-C1 growth in WT mice. Notably, while all mice 
previously vaccinated with either DC-PSCA or DC-STEAP experienced a 
delay in TRAMP-C1 growth, this was statistically significant only for STEAP-
vaccinated mice. Moreover, only DC-STEAP vaccinated mice maintained a 
STEAP-specific immune response at the time of sacrifice. For that reason we 
focused our attention on STEAP and tested its efficacy in TRAMP mice.  
Interestingly, and at difference with Tag (150), tumor-bearing TRAMP mice 
did not undergo full tolerance against STEAP, and STEAP-vaccinated 
TRAMP mice showed a delayed growth of subcutaneous TRAMP-C1 tumors, 
therefore confirming that STEAP-specific CTL remain functional in tumor 
bearing TRAMP mice. 
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PSCA showed in TRAMP mice an intermediate behavior:  although full 
tolerance was not reached in tumor-bearing mice, the persistent immune 
response was weaker than that against STEAP. 
Analysis of antigen expression in the prostate of TRAMP mice showed a 
different expression of the three antigens that inversely correlated with the 
antigen-specific immune response. 
Altogether, these data suggest that tolerance against this type of TAA follows 
the same rule of that induced for tissue-associated antigens in peripheral 
tissues: the more the antigen is expressed the more tolerance is profound. 
This information is fundamental for the choice of the antigen to be used in the 
clinic. 
It is also important to underline the different behavior of Tag and STEAP. 
Indeed, Tag showed a dynamic of tolerance induction that was comparable 
to other antigens whose expression was genetically manipulated in TRAMP 
mice (176-179). Conversely, tolerance to STEAP appears more similar to 
that found in cancer patients, therefore suggesting that preclinical research 
should focus more on the latter type of antigens. 
Sherman and collaborators (166) investigated in another mouse model the 
correlation between the amount of antigen expressed in the periphery and 
both the degree of T cell proliferation in lymph nodes and the rate of 
tolerance of antigen-specific CD8+ T cells.  In their studies in InsHA mice, 
they showed how homozygous InsHA mice had enhanced activation and 
proliferation of Kd-restricted HA-specific CD8+ T cells in the pancreatic lymph 
nodes following HA immunization, but these cells were rapidly deleted. In 
contrast, in heterozygous mice that have half of the antigen expressed, this 
deletion was less rapid. Nevertheless, a continuous Ag exposure could also 
induce clonal deletion or anergy of CD8+ T cells (167). This is what we 
believe occurs for Tag and PSCA, respectively, in TRAMP mice. The limited 
over-expression of STEAP even in advanced disease may protect STEAP-
specific clones from peripheral anergy/deletion. 
Based on these results, DC-STEAP immunization was tested in a 
prophylactic protocol in TRAMP mice. Despite the presence of STEAP-
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specific CTL even months after the priming, this strategy was not sufficient to 
prevent or arrest the growth of the autochthonous tumor, therefore 
suggesting that STEAP-specific CTL are qualitatively and quantitatively 
insufficient to cope with a massive neoplastic transformation of the whole 
TRAMP prostate. At least at the beginning, the situation in humans is 
expected to be well different: indeed, human prostate cancer generates from 
different small foci within the prostate gland. Hence, vaccination against 
STEAP may prove to be more efficacious in patients with a very early 
disease. This is a relevant issue for patients who may decide between 
watchful waiting and radical prostatectomy. Indeed, vaccination might 
represent a third option. 
The fact that STEAP-specific CTL persisted in vaccinated animals 
demonstrates how they could have escaped most of the immunosuppressive 
mechanisms that generally dampen the tumor-specific immune response in 
tumors. We have no clue on the mechanisms by which STEAP-specific T 
cells escaped tumor-induced tolerance in TRAMP mice. Tumor-specific CTL 
may encounter an immunosuppressive environment both in the lymph nodes 
at the time of priming or restimulation, as suggest by Hurwitz AA and 
collaborators (180), and at the tumor site (181). While the latter should 
involve all tumor infiltrating CTL, it might be possible that a high amount of 
antigen presented in the tumor draining lymph nodes rapidly consume the 
reservoir of antigen-specific CTL that, once activated, deploy to the tumor 
were they are eliminated. The relatively low expression of STEAP and the 
low affinity of STEAP-specific CTL may protect them from this consumption. 
An alternative or complementary explanation is that tumor-specific CTL are 
activated in many secondary lymphoid organs during tumor progression, with 
the exception of CTL specific for highly expressed antigens, which are 
concentrated in tumor draining lymph nodes where most of the 
immunosuppressive mechanisms are located.  
These results also suggested that vaccination targeting even more than one 
antigen at the time (as for example for GVAX and ProstVac trials) might have 
limited effects in advanced prostate cancer patients. For that reason, we 
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tested a combined therapy of allotransplantation and tumor-specific 
vaccination. The major goal was to eradicate established spontaneous 
prostate cancer and to induce a long-term immune response. Based on the 
previous results obtained in TRAMP mice (165), we set-up a non-
myeloablative treatment followed by a HCT, fDLI and a STEAP-specific 
vaccination. The aim of these experiments was also to test if a more realistic 
tumor antigen when compared to the oncogen-driven Tag IV could have the 
same therapeutic effects. 
The analysis of tumor-specific T cells responses in transplanted mice 
indicated that T cells of DLI origin were capable of a STEAP-specific 
response upon infusion and DC-STEAP vaccination in TRAMP mice. It is 
interesting to note that in this therapeutic setting, also host-derived cells 
surviving the pre-conditioning maintained the capacity to respond to the 
vaccine. Hence, combination of non-myeloablative conditioning, 
allotransplantation and vaccination, by simultaneously providing competent 
lymphocytes able to respond to the vaccination, appeared to recreate a 
correct milieu for the generation and the maintenance of an effective 
protective response. 
Minor H-specific T cells could have played a fundamental role in tumor 
regression. Probably, because of their female origin, they could have 
reached all the male organs, but particularly the prostate, because of the in 
situ inflammation and the release of TNF-alpha (174). Here they could have 
directly recognized H-Y peptides presented by the tumor cells or tumor-
associated stromal components, killed prostate cells, favoring the antigen 
shedding and the activation of tumor-specific T cells. This could have 
induced a local GVH response and tissue damage, which in turn might have 
contributed to tumor-specific T cell priming in tumor-draining lymph nodes. 
The analysis of the prostates demonstrated how allotransplantation and DC-
STEAP vaccination were able to significantly reduce tumor burden (Fig.13-
14).  
Optimal infiltration of T cells into the tumor mass is a critical issue, based on 
the fact that defined CD8+ T cells concentrations within the tumor mass are 
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needed for effective tumor clearance (173). The presence of a high number 
of CD3+ T cells in the prostates of allotransplantated and vaccinated mice 
demonstrated how these cells could have played a central role in killing 
tumor cells. Notably, an increased tumor infiltrate was observed also in mice 
that received the transplant setting followed by a DC unpulsed vaccination. 
Most likely, the shedding of tumor antigens in the prostates due to the DLI 
infusion, activation and subsequent killing of tumor cells could have activated 
DC and primed new CD3+ T cells.  
Taken together, these results demonstrated how tumor eradication requires 
the concomitance of minor and tumor-specific T cell responses.  
Previous studies investigated the possibility of breaking peripheral tolerance 
in TRAMP mice (168,169). All this works demonstrated how vaccination was 
able to delay autochthonous prostate cancer only when treatment started 
when animals were relatively young (10-12 week of age) and thus may not 
have mimicked the situation found in PC patients and in older TRAMP mice. 
Instead, in this study the efficacy of the treatment was tested in 16-week-old 
TRAMP mice, resembling an advanced stage of the disease and most 
importantly, an antigen, i.e. STEAP, that does not encounter peripheral 
tolerance was used. It will be important to verify if also DC-STEAP 
vaccination induces a long-lasting memory response that protect mice from 
tumor recurrence, as we have seen for DC-Tag (150). Another issue that 
needs to be addressed is that in humans, donors and recipients are 
mismatched for more than one minor H antigen. For that reason, experiments 
using female BALB/b mice as donor are carryed out, recapitulating a situation 
of multiple minor mismatches. 
All this work focused the attention on CD8+ T cells, but also other cellular 
types could have a role in the tumor control after allotransplantation. 
Sherman LA and collaborators demonstrated how CD4+ T cells play a 
central role in tumor regression, mobilizing effectors CD8+ T cells to 
peripheral tissues (175). Also NK cells that recognize NKG2D ligands on 
tumor cells could play a role in reducing prostate cancer progression in 
TRAMP mice, starting from the observation that TRAMP mice deficient for 
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NKG2D showed an increased incidence of aggressive tumors (170). Also γδ 
T cells are involved in prostate cancer progression in the TRAMP model: 
mice lacking these cells develop large tumors in comparison to normal ones 
(171). Experiments are ongoing to identify the respective targets of allo-and 
tumor-specific T cells in transplanted mice (Hess Michelini R et.al. 
Manuscript in preparation). 
Taken together, the results obtained in this thesis demonstrate how STEAP-
specific vaccination can induce a long-lasting immune response in TRAMP 
mice, mainly due to its low expression at the tumor site. While vaccinations 
targeting antigens like STEAP might be proposed to patients with high 
probability to develop prostate cancer or for those with a low-risk prostate 
cancer, a combination of allo-transplantation, DLI and vaccination might be a 
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